Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airleaf dose-finding study of BI 1291583 in bronchiectasis
NL-OMON53709Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first pulmonary exacerbation. Started Sep 2022; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON53709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53709.